all report title image
  • Published In : Sep 2023
  • Code : CMI4332
  • Pages : 156
  • Formats :
      Excel/PDF
  • Industry : Pharmaceutical

Thrombocytopenia is a condition in which blood platelets are low in person’s body. Thrombocytes are colourless blood cells that help blood clot. Thrombocytopenia is common in cancer patients. The occurrence of chemotherapy-induced thrombocytopenia varies from person to person depending on the treatment used. Each chemotherapy agent differs in how it causes thrombocytopenia. Mostly chemotherapy-induced thrombocytopenia are caused by the gemcitabine-and platinum-based regimens used in chemotherapy. Alkylating agents affect stem cells, cyclophosphamide affects later megakaryocyte progenitors, bortezomib prevents platelet release from megakaryocytes, and some treatments promote platelet apoptosis. Thrombocytopenia can also occur with any infection or adverse drug reaction associated with cancer treatment. Chemotherapy-induced therapy can be particularly harmful, as it can delay chemotherapy, decrease the dose of chemotherapy drugs, increase medical expenses, and can cause induced bleeding.

Market Dynamics

The increasing number of cancer cases is expected to surge the number of chemotherapy procedures, and this is expected to drive the Euopean chemotherapy-induced thrombocytopenia therapeutics market. For instance, according to the World health Organization (WHO), over 3.7 million new cancer cases and 1.9 million death occur each year, and cancer represents the second most important cause of death and morbidity in 2012 in Europe, on a global scale, cancer accounted for 8.2 million deaths   Currently, there are no approved treatments available for (chemotherapy-induced thrombocytopenia) CIT in the European Union.

However, growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period, owing to discontinuation of clinical trials due to failure of chemotherapy-induced thrombocytopenia therapeutics. For instance, in October 2020, Swedish Orphan Biovitrum AB announced results of its phase III study of Avatrombopag (Doptelet), an oral thrombopoietin (TPO) receptor agonist, in solid tumor cancer patients with chemotherapy-induced thrombocytopenia (CIT). The study failed to meet the primary end point of avoiding platelet transfusions chemotherapy dose reductions by 15% or greater and also failed to show efficacy in chemotherapy-induced thrombocytopenia.

Key features of the study:

  • This report provides in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market size (US$ 1,866.4 Mn) by 2027, and compound annual growth rate (CAGR) 5.0% for the forecast period: 2020-2027, considering 2019 as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
  • It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen, Inc., Novartis AG., Pfizer Inc., LLC, Swedish Orphan Biovitrum AB., Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for dialysis market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class:
    • Thrombopoietin Receptor Agonists
    • Thrombopoietic Agents
      • Others
  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel:
    • Hospital Pharmaciesa
    • Retail Pharmacies
    • Online Pharmacies
  •  Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Thrombopoietin Receptor Agonists
        • Thrombopoietic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis AG
    • Pfizer Inc.
    • Swedish Orphan Biovitrum AB
    • Jiangsu HengRui Medicine Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trend
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Pipeline Analysis
    • Acquisition and Collaboration Scenario
  4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis
    • COVID-19 Epidemiology
    • Overall Impact on the Healthcare Sector
    • Total Impact of COVID-19 on the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market
    • Supply and Demand Analysis
  5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • Thrombopoietin Receptor Agonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
    • Thrombopoietin Receptor Agonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
  6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
  7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
      • Segment Trends
  8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2018-2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018-2030
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Swedish Orphan Biovitrum AB
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Jiangsu HengRui Medicine Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 21 market data tables and 25 figures on “Global Chemotherapy-induced Thrombocytopenia Therapeutics Market”- Global forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo